Macter International Limited

MACTER

PK0113501016

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
85 ^PKR	-5.56%		-8.36%	-3.41%

Mar. 12	Macter International Limited Announces Board Changes	CI
Jan. 09	Macter International Limited Announces Appointment of Syed Naveed Rizvi as Chief Financial Officer, Effective from January 08, 2024	CI

Macter International Limited Announces Unconsolidated Earnings Results for the Year Ended June 30, 2021

October 01, 2021 at 03:21 am EDT

Macter International Limited announced unconsolidated earnings results for the year ended June 30, 2021. For the year, the company reported net profit of PKR 257,028,000 against PKR 14,930,000 a year ago.

Latest news about Macter International Limited

Macter International Limited Announces Board Changes	Mar. 11	CI
Macter International Limited Announces Appointment of Syed Naveed Rizvi as Chief Financial Officer, Effective from January 08, 2024	Jan. 09	CI
Macter International Limited Announces Resignation of Syed Anis Ahmed Shah as Director	Dec. 13	CI
Macter International Limited Proposes Final Cash Dividend for the Financial Year Ending June 30, 2023	23-09-27	CI
Macter International Limited Announces Change of Director	23-05-08	CI
Macter International Limited Announces Cease of Tariq Wajid as Director	23-02-09	CI
Macter International Limited Announces Executive Changes	22-03-17	CI
Macter International Limited Announces Board Changes	22-01-20	CI
Macter International Limited Announces Cessation of Sohaib Umar as Director	21-10-25	CI
Macter International Limited Announces Unconsolidated Earnings Results for the Year Ended June 30, 2021	21-10-01	CI
Macter International Limited Recommends Cash Dividend for the Year Ended June 30, 2021	21-09-20	CI
Macter International Limited Announces Unaudited Earnings Results for the Second Quarter and Half Year Ended December 31, 2020	21-02-17	CI
Macter International Limited Declares Interim Cash Dividend	21-02-17	CI
Macter International Limited Announces Unconsolidated and Consolidated Earnings Results for the Year Ended June 30, 2020	20-10-05	CI
Macter International Limited Reports Unaudited Un-Consolidated and Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2020	20-04-30	CI
Macter International Limited Reports Un-Consolidated and Consolidated Unaudited Financial Results for the Second Quarter and Six Months Ended December 31, 2019	20-02-26	CI
Macter International Limited Announces Unaudited Unconsolidated Earnings Results for the Quarter Ended September 30, 2019	19-10-29	CI
Macter International Limited Proposes Final Cash Dividend for the Year Ended June 30, 2019	19-10-04	CI
Macter International Limited Announces Earnings Results for the Year Ended June 30, 2019	19-10-04	CI
Macter International Limited Reports Unaudited Unconsolidated and Consolidated Earnings Results for the Quarter and Nine Months Ended March 31, 2019	19-04-30	CI
Macter International Limited Reports Un-Consolidated Unaudited Financial Results for the Second Quarter and Six Months Ended December 31, 2018	19-02-27	CI
Macter International Limited Reports Earnings Results for the Quarter Ended September 30, 2018	18-10-30	CI
Macter International Limited Reports Earnings Results for the Year Ended of June 30, 2018	18-10-03	CI
Macter International Limited Announces Executive Changes	18-10-03	CI
Macter International Limited Appoints Masarrat Misbah as its Director in Place of Muhammad Sajid	18-08-01	CI

Chart Macter International Limited

Duration

Period

More charts

Company Profile

Macter International Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is to manufacture and market pharmaceutical products. The Companyâs business areas are contract manufacturing and branded generic formulations. It is a contract manufacturer for multinational companies, which offers a range of dosage forms: oral solids and liquids, parenteral (ampules and vials), topicals, metered dose inhalers, ear and eye drops. Its contract manufacturing clients include a number of blue-chip multinationals. The Company produces specialty products at its high-tech plant. These include solid and liquid oral dosage forms (tablets, capsules, syrups, suspensions and dry powder), injections (sterile liquid vials, sterile liquid ampoules and sterile dry powders), ointments and creams, drops and inhalers. Its manufacturing operations include formulation, vial filling, lyophilization and packaging of biological drugs.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MACTER INTERNATIONAL LIMITED	-3.41%	14.81M
ELI LILLY AND COMPANY	+25.80%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.69%	352B
MERCK & CO., INC.	+19.01%	332B
ABBVIE INC.	+3.22%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.23%	145B

Other Pharmaceuticals